Quantbot Technologies LP Takes Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Quantbot Technologies LP bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 25,454 shares of the company’s stock, valued at approximately $945,000.

Several other hedge funds have also added to or reduced their stakes in AMPH. Smartleaf Asset Management LLC increased its holdings in shares of Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust increased its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its position in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Amphastar Pharmaceuticals by 22.7% during the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after purchasing an additional 388 shares during the period. Finally, KBC Group NV grew its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 27.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $28.39 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm’s fifty day simple moving average is $31.52 and its 200 day simple moving average is $40.24. The stock has a market cap of $1.35 billion, a P/E ratio of 9.46, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a twelve month low of $25.89 and a twelve month high of $53.96.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.